chr19-11033791-G-A

Variant summary

Our verdict is Likely benign. The variant received -1 ACMG points: 2P and 3B. PM2BP4_ModerateBP6

The NM_001387283.1(SMARCA4):​c.3799G>A​(p.Gly1267Ser) variant causes a missense change. The variant allele was found at a frequency of 0.00000513 in 779,766 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G1267D) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.000020 ( 0 hom., cov: 33)
Exomes 𝑓: 0.0000016 ( 0 hom. )

Consequence

SMARCA4
NM_001387283.1 missense

Scores

9
9

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:2B:1

Conservation

PhyloP100: 3.86

Publications

4 publications found
Variant links:
Genes affected
SMARCA4 (HGNC:11100): (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4) The protein encoded by this gene is a member of the SWI/SNF family of proteins and is similar to the brahma protein of Drosophila. Members of this family have helicase and ATPase activities and are thought to regulate transcription of certain genes by altering the chromatin structure around those genes. The encoded protein is part of the large ATP-dependent chromatin remodeling complex SNF/SWI, which is required for transcriptional activation of genes normally repressed by chromatin. In addition, this protein can bind BRCA1, as well as regulate the expression of the tumorigenic protein CD44. Mutations in this gene cause rhabdoid tumor predisposition syndrome type 2. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2012]
SMARCA4 Gene-Disease associations (from GenCC):
  • Coffin-Siris syndrome
    Inheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet, Illumina
  • intellectual disability, autosomal dominant 16
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • rhabdoid tumor predisposition syndrome 2
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, ClinGen, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), G2P
  • uterine corpus sarcoma
    Inheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
  • familial rhabdoid tumor
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • hereditary nonpolyposis colon cancer
    Inheritance: AD Classification: LIMITED Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_benign. The variant received -1 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.2387389).
BP6
Variant 19-11033791-G-A is Benign according to our data. Variant chr19-11033791-G-A is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 480652.

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_001387283.1. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
SMARCA4
NM_001387283.1
MANE Plus Clinical
c.3799G>Ap.Gly1267Ser
missense
Exon 27 of 36NP_001374212.1
SMARCA4
NM_003072.5
MANE Select
c.3799G>Ap.Gly1267Ser
missense
Exon 27 of 35NP_003063.2
SMARCA4
NM_001128849.3
c.3799G>Ap.Gly1267Ser
missense
Exon 27 of 36NP_001122321.1

Ensembl Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
SMARCA4
ENST00000646693.2
MANE Plus Clinical
c.3799G>Ap.Gly1267Ser
missense
Exon 27 of 36ENSP00000495368.1
SMARCA4
ENST00000344626.10
TSL:1 MANE Select
c.3799G>Ap.Gly1267Ser
missense
Exon 27 of 35ENSP00000343896.4
SMARCA4
ENST00000643995.1
c.3211G>Ap.Gly1071Ser
missense
Exon 24 of 32ENSP00000496004.1

Frequencies

GnomAD3 genomes
AF:
0.0000197
AC:
3
AN:
152146
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.0000241
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000294
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.00000408
AC:
1
AN:
245330
AF XY:
0.00000746
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.00000159
AC:
1
AN:
627620
Hom.:
0
Cov.:
0
AF XY:
0.00000292
AC XY:
1
AN XY:
341942
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
17696
American (AMR)
AF:
0.00
AC:
0
AN:
43736
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
20982
East Asian (EAS)
AF:
0.00
AC:
0
AN:
36070
South Asian (SAS)
AF:
0.0000143
AC:
1
AN:
69798
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
51886
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
4150
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
350234
Other (OTH)
AF:
0.00
AC:
0
AN:
33068
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.525
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000197
AC:
3
AN:
152146
Hom.:
0
Cov.:
33
AF XY:
0.0000404
AC XY:
3
AN XY:
74322
show subpopulations
African (AFR)
AF:
0.0000241
AC:
1
AN:
41436
American (AMR)
AF:
0.00
AC:
0
AN:
15276
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5182
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4834
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10602
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
0.0000294
AC:
2
AN:
68024
Other (OTH)
AF:
0.00
AC:
0
AN:
2094
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.475
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00
Hom.:
0
Bravo
AF:
0.0000113
ExAC
AF:
0.00000825
AC:
1

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:2Benign:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Intellectual disability, autosomal dominant 16 Uncertain:1
Jul 15, 2021
Genome-Nilou Lab
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Rhabdoid tumor predisposition syndrome 2 Uncertain:1
Oct 17, 2022
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 1267 of the SMARCA4 protein (p.Gly1267Ser). This variant is present in population databases (rs764152134, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with SMARCA4-related conditions. ClinVar contains an entry for this variant (Variation ID: 480652). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

Hereditary cancer-predisposing syndrome Benign:1
Jun 14, 2023
Ambry Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.071
BayesDel_addAF
Uncertain
0.012
T
BayesDel_noAF
Benign
-0.12
CADD
Uncertain
25
DANN
Uncertain
0.99
DEOGEN2
Benign
0.24
T
Eigen
Uncertain
0.51
Eigen_PC
Uncertain
0.55
FATHMM_MKL
Uncertain
0.95
D
LIST_S2
Uncertain
0.89
D
M_CAP
Benign
0.045
D
MetaRNN
Benign
0.24
T
MetaSVM
Uncertain
0.39
D
MutationAssessor
Benign
0.42
N
PhyloP100
3.9
PrimateAI
Uncertain
0.64
T
PROVEAN
Benign
-0.44
N
REVEL
Uncertain
0.34
Sift
Benign
0.11
T
Sift4G
Benign
0.47
T
Polyphen
1.0
D
Vest4
0.34
MutPred
0.22
Loss of glycosylation at S1266 (P = 0.0239)
MVP
0.81
MPC
1.4
ClinPred
0.41
T
GERP RS
5.2
PromoterAI
-0.0014
Neutral
Varity_R
0.12
gMVP
0.66
Mutation Taster
=93/7
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs764152134; hg19: chr19-11144467; API